Myriad Genetics Inc (MYGN): R&D Expense
$106.80M
Year ended 2025-12-31
$105.80M
Trailing 12 months to 2026-06-30
+7.7%
3-year compound annual growth
+7.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $106.80M | -5.8% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $113.40M | +27.8% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $88.70M | +3.9% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $85.40M | +4.3% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $81.90M | +11.7% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $73.30M | n/a | 2022-02-25, From 2020-01-01 |
| No annual figure between 2019-06-30 and 2020-12-31. | |||
| 2019-06-30 | $85.90M | +21.3% | 2022-02-25, From 2018-07-01 |
| 2018-06-30 | $70.80M | -4.8% | 2020-08-13, From 2017-07-01 |
| 2017-06-30 | $74.40M | +5.4% | 2019-08-13, From 2016-07-01 |
| 2016-06-30 | $70.60M | -6.5% | 2018-08-24, From 2015-07-01 |
| 2015-06-30 | $75.50M | +11.9% | 2018-08-24, From 2014-07-01 |
| 2014-06-30 | $67.50M | +25.7% | 2016-08-10, From 2013-07-01 |
| 2013-06-30 | $53.70M | +25.9% | 2015-08-12, From 2012-07-01 |
| 2012-06-30 | $42.65M | +53.7% | 2014-08-13, From 2011-07-01 |
| 2011-06-30 | $27.75M | +26.9% | 2013-08-14, From 2010-07-01 |
| 2010-06-30 | $21.87M | +22.1% | 2012-08-15, From 2009-07-01 |
| 2009-06-30 | $17.91M | n/a | 2011-08-15, From 2008-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $106.80M | -5.8% |
| Neogen Corp (NEOG) | 2026-05-31 | $18.40M | -12.8% |
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $177.31M | +5.5% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $186.20M | -14.9% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $251.21M | +14.3% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $388.86M | -16.6% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $2.20M | -20.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.04M | -22.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $2.88M | -11.9% |
Compare MYGN, NEOG, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗